Zobrazeno 1 - 10
of 490
pro vyhledávání: '"Davies, JC"'
Autor:
Sandhu, D, Redmond, JL, Smith, NMJ, Short, C, Saunders, CJ, Couper, JH, Fullerton, CJ, Richmond, G, Talbot, NP, Davies, JC, Ritchie, GAD, Robbins, PA
This study explored the use of computed cardiopulmonography (CCP) to assess lung function in early-stage cystic fibrosis (CF). CCP has two components. The first is a particularly accurate technique for measuring gas exchange. The second is a computat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::891cd242c8d3efe4e44ed37b470fd44e
http://hdl.handle.net/10044/1/105382
http://hdl.handle.net/10044/1/105382
Publikováno v:
The Application of Clinical Genetics, Vol 2012, Iss default, Pp 29-36 (2012)
Tabinda J Burney1,2, Jane C Davies1,2,31Department of Gene therapy, Imperial College London, 2UK CF Gene Therapy Consortium London, 3Department of Paediatric Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UKAbstract:
Externí odkaz:
https://doaj.org/article/722bed43a264479d950a4202cab37792
Autor:
De Wachter, E, Davies, JC, Simmonds, NJ, Castellani, C, de Winter-de Groot, KM, Munck, A, Proesmans, M, Southern, KW, Barben, J
Publikováno v:
In Journal of Cystic Fibrosis January 2024 23(1):176-177
Autor:
Davies, JC, Drevinek, P, Elborn, JS, Kerem, E, Lee, T, European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF’, Amaral, MD, De Boeck, K
Publikováno v:
Journal of Cystic Fibrosis. 18:677-684
The last decade has witnessed developments in the CF drug pipeline which are both exciting and unprecedented, bringing with them previously unconsidered challenges. The Task Force group was brought together to consider these challenges and possible s
This article was originally published with the sentence “Thank you for the opportunity to respond to the correspondence by J.G. Nielsen from Innovision about our recent paper”. The authors have since been made aware that J.G. Nielsen sold Innovis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffeaba0d5c041308f6e9d8941bc5920d
http://hdl.handle.net/10044/1/79776
http://hdl.handle.net/10044/1/79776
Autor:
Davies, JC, Scott, S, Dobra, R, Brendell, R, Brownlee, K, Carr, SB, Cosgriff, R, Simmonds, NJ, London Network of Clinical Trials Accelerator Platform sites, Jahan, R, Jones, A, Matthews, J, Brown, S, Galono, K, Miles, K, Pao, C, Shafi, N, Watson, D, Orchard, C, Davies, G, Pike, K, Shah, S, Bossley, CJ, Fong, T, Macedo, P, Ruiz, G, Waller, M, Baker, L
Publikováno v:
e50
e48
e48
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96e275c0f439bb5ccb9f1ae0e40f9a1d
http://hdl.handle.net/10044/1/76458
http://hdl.handle.net/10044/1/76458
Autor:
Amaral, MD, De Boeck, K, On behalf of the ECFS Strategic Planning Task Force on ‘Speeding up access to new drugs for CF’, Amaral, M, Davies, JC, Drevinek, P, Elborn, S, Kerem, E, Lee, T
The last decade has witnessed developments in the CF drug pipeline which are both exciting and unprecedented, bringing with them previously unconsidered challenges. The Task Force group came together to consider these challenges and possible strategi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf78c0a569691bbdd58b6b8a411166db
http://hdl.handle.net/10044/1/71973
http://hdl.handle.net/10044/1/71973
Autor:
Rosenfeld, M, Cunningham, S, Harris, WT, Lapey, A, Regelmann, WE, Sawicki, GS, Southern, KW, Chilvers, M, Higgins, M, Tian, S, Cooke, J, Davies, JC, KLIMB study group
Publikováno v:
JOURNAL OF CYSTIC FIBROSIS
Background KIWI (NCT01705145) was a 24-week, single-arm, pharmacokinetics, safety, and efficacy study of ivacaftor in children aged 2 to 5 years with cystic fibrosis (CF) and a CFTR gating mutation. Here, we report the results of KLIMB (NCT01946412),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6ab455f0141a6bfd51073eb78b59ef
http://hdl.handle.net/10044/1/71513
http://hdl.handle.net/10044/1/71513